Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD20 immunotargeting in stage IV melanoma
2010-023277-19Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Apr 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in melanoma, sponsored by Medical University of Vienna. Primary endpoint: Overall tumor response rate. Started Apr 2011; status: completed.
02
Drugs
rituximab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2010-023277-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023277-19.